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Abstract 
Purpose: To detect efflux pump activity (EPA) and screening a suspected efflux pump inhibitor (EPI) [1-
(3-(trifluoromethyl)benzyl]-piperazine (TFMBP)], which could help in reducing multi-drug resistance 
(MDR).  
Methods: Eighteen isolates, viz, 14 S. aureus, 2 S. lentus, 1 S. xylosus and 1 Micrococcus species 
from various hospital infections of admitted patients were screened for antibiotics susceptibility to 11 
classes of antibiotics including oxacillin and β-lactamase production. Efflux pump activity (EPA) was 
determined by minimum inhibitory concentration (MIC) technique in the presence and absence of 
TFMBP, the isolates were also screened for MDR genes.   
Results: All the isolates were resistant to ampicillin (10 µg) and penicillin (10 µg), but sensitive to 
bacitracin (10 µg). Majority of the isolates were MDR 12/18 (66.7 %), 10 (55.6 %) were inducible β-
lactamase producers and 3 (16.7 %) were intrinsic β-lactamase producers. Seven (38.9 %) were 
resistant to oxacillin and also produced carbapenemase enzyme. Eight (66.7 %) of the 12 MDR isolates 
gave evidence of EPA with TFMBP. However, no MDR genes were detected. 
Conclusion: Staphylococcus and Micrococcus species exhibit EPA in antibiotic resistance while a 
suitable EPI such as TFMBP when combined with specific antibiotics could help combat this menace. 
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Antibiotic drug development has dropped by 
about 75 % since the 1980s [1,2] especially 
between 1962 and 2000. Despite the occurrence 
of methicillin-resistant Staphylococcus aureus 
(MRSA) reported in Nigerian secondary and 
tertiary hospitals [3-5], there is still a dearth of 
information on prevalence and types of 
multidrug-resistant (MDR) strains among 
Staphylococcus species, in Nigeria and sub-
saharan Africa [6]. With more insight into the 
knowledge of the mechanisms of resistance in 
MDR bacteria, new initiatives in research into 
formulation of newer antibiotics or fortification of 
the existing ones for combating multi-drug 
resistant organisms will develop. 
 
The typical phenotype of MRSA is multiple 
resistance to penicillin, oxacillin, cefuroxime, 
ciprofloxacin, erythromycin, clindamycin, 
sulphamethoxazole, and gentamicin, amongst 
other classes of antibiotics [7]. MDR exhibited by 
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bacterial organisms to chemically-unrelated 
antibacterial agents are caused by over-
expression of MDR efflux pumps (which are 
transport proteins). This process leads to the 
extrusion of toxic substances including clinically-
relevant antibiotics (which help in combating the 
pathogenic organisms) into the external 
environment.  These pump proteins are found in 
both Gram-positive and Gram-negative bacteria, 
as well as in eukaryotic organisms [8]. 
 
Bohnert and Kern [8], studied a number of 
arylpiperazines for their ability to reverse multi-
drug resistance in E. coli over-expressing RND 
(Resistance Nodulation-Division) efflux pumps. 
Among them, 1-[3-(trifluoromethyl) benzyl]-
piperazine (TFMBP) (200 µg/mL) was found to 
lower the effective MIC of levofloxacin four-fold.  
In recent times, antimicrobial resistance 
phenotypes are predicted by identifying and 
characterising the known genes that encode the 
specific resistance mechanisms. The methods of 
Polymerase Chain Reaction (PCR) and DNA 
sequencing are known to offer the promise of 
increased sensitivity, specificity and speed in the 
detection of such specific known resistance 
genes [9,10]. Therefore, this study was 
conducted to identify and determine the genes 
responsible for efflux pump activity in different 
isolates of Staphylococcus and Micrococcus 






Eighteen clinical isolates comprising of 14 S. 
aureus, 2 S. lentus, 1 S. xylosus and 1 
Micrococcus spp. from infections of urinary tract, 
upper respiratory tract, ear and eye swab, and 
blood culture all were identified by the analytical 
profile index (API) and the analytical profile index 
web (APIWeb) were used. S. aureus (ATCC 
25923) was used as the standard strain in the 
study. 
 
Antibiotics susceptibility test 
 
Antibiotics susceptibility testing was carried out 
as described by Bauer et al [11] on the isolates. 
Ampicillin-10 µg (Amp-10), penicillin-G 10 µg (P-
10), ceftriaxone-30 µg (CRO-30), ciprofloxacin-5 
µg (CIP-5), tetracycline-30 µg (Te-30), 
cotrimoxazole-1.25 µg + 23.75 µg (SXT-
1.25/23.75), neomycin-30 µg (N-30), erythro-
mycin-15 µg (E–15), polymyxin-B-300 i.u. (PB-
300), lincomycin-2 µg (L-2), chloramphenicol-30 
µg (C-30) and bacitracin-10 µg (B-10) 
representing 11 classes of antibiotics were used. 
For further testing, all strains found to be 
resistant to four or more classes of antibiotics 
were classified as MDR. 
 
β- Lactamase assay 
 
All isolates showing resistance to the β-lactam 
antibiotics were further tested for the production 
of β-lactamase enzyme using nitrocefin (NF), a 
“colour shift substrate” as described by 
Livermore and Brown [12]. The standard strains, 
E. coli A (non β-lactamase producing) and E. coli 
B (β-lactamase producing) used were collected 
from McNeil Science and Technology culture 
collection Centre (Usciences, Philadelphia). The 
tests were performed as follows; In the blank 
assay, 0.25 mL sterile Mueller Hinton Broth 
(MHB) and 0.25 mL of NF assay solution was 
added to the 0.5 mL of 0.01 M Na-HEPES, while 
in the  reaction assay the 0.25 mL  sterile MHB 
was replaced with 0.25 mL of broth culture. A 
color change from yellow to red in the reaction 
solution within 10 minutes compared with the 
blank was indicative of the presence of intrinsic 
β-lactamase producer [12]. While, strains 
showing the color change after 10 min were 
considered as inducible β-lactamase producers 
[12]. 
 
Detection of antibiotic resistance with the 
modified double disc synergy test (MDDST) 
 
A twelve-disk procedure was carried out on the 
MDR isolates with the antibiotics CRO-30, 
ceftazidime-30µg/clavulanate-10µg (CAZ/CLA-
30/10), ceftazidime-30µg (CAZ-30), cefepime-30 
µg (FEP-30), cefoxitin-30 µg (FOX-30), 
aztreonam-30 µg (ATM-30), eterpenem-10 µg 
(ERT-10), imipenem-10 µg (IMP-10), oxacillin-1 
µg (OX-1), vancomycin-30 µg (Va-30), ampicillin-
20 µg / clavulanic acid-10 µg (AmC-30), and 
ampicillin-10 µg / sulbactam-10 µg (SAM-20). 
Zones of inhibition obtained were compared with 
the Zone Diameter Interpretative Standards from 
the disc manufacturers and CLSI. These were 
used to classify each organism as resistant, 
intermediate or susceptible to the antibiotics [13]. 
 
Efflux pump activity (EPA) test 
 
MDR isolates were further tested for EPA. The 
MICs of the test drugs were determined in the 
presence and absence of TFMBP as EPI. A 
reduction in MIC in the presence of the EPI 
indicates resistance due to EPA in the MDR 
isolates [8]. 
 
Eleven of the isolates tested (of which seven 
were found to be Oxacillin resistant S. aureus 
ORSA  from the MDDST), were picked for this 
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test. The four drugs used in this test were 
amoxicillin, cefuroxime, ciprofloxacin and 
tetracycline. These represent four classes of 
antibiotics to which the MDR organisms were 
commonly resistant. A total of 37 tests were 
performed using amoxicillin – 11 isolates, 
cefuroxime - 7 isolates, ciprofloxacin - 8 isolates, 
and tetracycline -11 isolates. 
 
Method 1: Broth macro-dilution 
 
The broth macro-dilution (tube method) was used 
to determine initial range of the MICs of these 
drugs against the isolates. Four milliliters of 
sterile Mueller Hinton broth (MHB) containing 
serially diluted antibiotic in each of 11 test tubes, 
beginning with 1000 µg/mL of test antibiotic in 
tube no. 1 to 0.9765 µg/mL in the 11th tube were 
set up for the test. Tubes 12 and 13 containing 4 
mL of MHB were also set up as growth and 
sterile controls. Overnight fresh broth (18 h) 
culture of each isolate was diluted to give a 1:103 
dilution in normal saline (equivalent to 0.5 
McFarland standard), and 0.1 mL of this was 
introduced into each tube from the second tube 
to the 12th tube. The twelfth tube, which 
contained no antibiotic was the growth control, 
while the 13th tube with only 4 mL of sterile MHB 
served as the sterility control. All of the tubes 
from the 2nd to the 13th were incubated at 35 oC 
for 18 h. 
 
The MIC was thereafter determined by 
measuring optical density (OD) at 550 nm in a 
Spectronic Thermo 20 Genesys spectropho-
tometer against an un-inoculated MHB as the 
reference blank. The tube with the lowest 
concentration that completely inhibited growth 
was taken as the MIC. A similar procedure was 
carried out for each of the antibiotics tested. 
 
Method 2: Broth micro-dilution 
 
MDR isolates were subjected to another round of 
MIC tests employing the micro-dilution assay 
method in micro-titer plates. The 96-well micro-
titer plates were used to perform the MIC tests at 
different concentrations of the antibiotics against 
the bacterial strains based on the result of the 
initial macro-dilution assay.  
 
The desired range of concentrations of each 
antibiotic for the MIC tests was initially obtained 
through serial double-dilution of each antibiotic in 
a twelve-channel basin. Sterile phosphate buffer, 
pH 6.0 was used as diluent for amoxicillin and 
cefuroxime while sterile water was used for 
tetracycline and ciprofloxacin. In the case of each 
antibiotic, starting with a stock concentration of 
2000 µg/mL in channel 1 of a twelve-channel 
basin, the serial double dilution was carried out 
up to a final concentration of 0.97663 µg/mL in 
the 12th channel. 
 
One micro-titer plate was used to test two 
different drugs (in duplicates) at a time and at ten 
different concentration levels from well A1 to well 
H10. The 11th column of wells (A11-H11) was for 
the growth control of the strain, while the 12th 
column of wells (A12-H12) was for a sterility 
control of the process (Table 1). 
 
Preparation of microdilutions in microtiter 
plate 
 
EPA test for each drug was done in duplicate in 
the micro-titer plate. For example, rows A and B 
were for amoxicillin with TFMBP, C and D for 
amoxicillin without TFMBP, E and F for 
cefuroxime with TFMBP, and G and H for 
cefuroxime without TFMBP. This was done for all 
the drugs used. 
 
Table 1 shows materials required per column in 
each row of wells for MIC determination in the 
presence of the EPI. 
 
For determination of MICs in the absence of the 
EPI, 34 µL of make-up volume of sterile 
phosphate buffer or sterile water (for water 
soluble antibiotics) was added instead.  
 
Thirty-seven EPA tests were carried out as 
specified in Table 1. The plates were then 
incubated at 35 oC for 18 h. after which the 
optical density (OD) of each well in the plates, 
were read at 650 nm in a micro-titer plate reader, 




The DNA of the isolates were extracted and the 
genotyping was done by Randomly-Amplified 
Polymorphic DNA (RAPD)-PCR and the PCR 
products were analysed using the agarose gel 
electrophoresis [14]. DNA quantification and 
check for purity was also done as described in 
literature [14]. For each chromosomal DNA 
sample, a PCR mix of 25 µL containing 
magnesium chloride (6 %; 1.5 µL), forward and 
reverse primers (0.8 %; 0.2 µL each) for each of 
the genes to be screened was used. The PCR 
was conducted by an initial denaturation at 95 oC 
for 5 min. followed by 30 cycles of denaturation 
at 95 oC for 30 sec. 
 
The annealing step was done for 60 sec. at 
various temperatures to suit each primer pair 
followed by elongation at 72 oC for 60 sec 
according to the manufacturer's specification.  
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Table 1: Composition of microtiter wells for MIC determination in the presence of 200 µg/mL of TFMBP 
 
Variable 1 2 3 4 5 6 7 8 9 10 11 12 
MHB (µl) 111 111 111 111 111 111 111 111 111 111 111 111 
Drug (µl) 50 50 50 50 50 50 50 50 50 50 0 0 
TFMBP stock (µl) 
 ( 1179 µg/ml) 
34 34 34 34 34 34 34 34 34 34 0 0 
Make up 
water/buffer (µl) 
0 0 0 0 0 0 0 0 0 0 84 89 
Broth culture (µl) 5 5 5 5 5 5 5 5 5 5 5 0 
Total Volume/well 
(µl)  




125 62.5 31.25 15.63 7.83 3.91 1.95 0.97 0.49 0.24 0 0 
Drug Stock 
solution µg/ml 





Table 2: Nucleotide sequence of primers used 
 
Primer Nucleotide sequence Phenotype 
Nor A-F (EFFLUX)           5’-ACT ATA CAC AGC TGA CAA GG- 3’ Efflux pump activity 
Nor A-R (EFFLUX)           5’-GAA TTA GGT ATG TGG ATT GC-3’ Efflux pump activity 
Nor A2-F (RES) 5’-TCG CCA TTC GGT GGT ACG TTA GC- 3’ Efflux pump activity 
Nor A2-R (RES) 5’-AAC CCA CCT GCA AAT CCC TGT CT- 3’ Efflux pump activity 
mecA-F AAA ATC GAT GGT AAA GGT TGG C Oxacillin resistant S. aureus 
mecA-R AGT TCT GCA GTA CCG GAT TTG C Oxacillin resistant S. aureus 
Luk-PV-1 ATC ATT AGG TAA AAT GTC TGG ACA TGA TCC A Oxacillin resistant S. aureus 
Luk-PV-2 GCA TCA AGT GTA TTG GAT AGC AAA AGC Oxacillin resistant S. aureus 
 
The final elongation step was done at 72 oC for 
10 min. The primers used for the PCR were as 
listed in Table 2 for Nor-A (efflux), Nor-A 




Data entry, coding, cleaning and analysis were 
done using Excel 2013 software. Descriptive 





Antibiotics susceptibility  
 
All of the clinical isolates tested in this study were 
resistant to Amp-10 and P-10 but sensitive to B-
10. Most of the isolates were sensitive to C-30 
(88.8 %) and SXT-1.25/23.75 (66.7 %) (Table 3). 
Among the 18 clinical isolates tested, 12 isolates 
(66.7 %) were found to be MDR. Of these, eight 
isolates were S. aureus (66.7 %), two S. lentus 
(16.7 %), one S. xylosus (8.3 %), and one 
Micrococcus sp. (8.3 %). Ten (55.6 %) of the 18 
isolates were inducible β-lactamase producers, 
three (16.7 %) were intrinsic β-lactamase 
producers, and five (27.7 %) had no β-lactamase 
activity (Figure 1). 
Oxacillinase and carbapenemase from 
MDDST 
 
Five S. aureus isolates (27.8 %) and one S. 
lentus (5.6 %) were ORSA and carbapenemase 
producers while the only Micrococcus sp. (5.6 %) 
tested was MDR, ORSA, and a carbapenemase 
producer (Figure 1). 
 
EPA with TFMBP 
 
Of the 12 MDR isolates tested, nine (75.0 %) 
gave evidence of EPA against at least one of the 
tested antibiotics. The only Micrococcus sp. 
tested showed EPA against three drugs and a 
16-fold reduction in MIC for only ciprofloxacin 
when TFMBP was used (Table 4). 
 
MDR and EPA genes  
 
No MDR and EPA genes were detected in the 
screened isolates in this study (Figure 2). There 
were no amplifications for any gene detection 
from all the primers used such as NorA 
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       Table 3: Antibacterial susceptibility of the clinical isolates 
 
Antimicrobial agent  No of 
isolates 
tested 
Sensitive Intermediate      Resistant 
N %  N %  N %  
Ampicillin 30 µg 18 0 0 0 0 18 100 
Penicillin G 10 µg 18 0 0 0 0 18 100 
Ceftriaxone 30 µg 18 11 61.1 1 5.6 6 33.3 
Ciprofloxacin 5 µg 18 9 50 3 16.7 6 33.3 
Tetracycline 30 µg 18 2 11.1 1 5.6 15 83.3 
SXT-1.25/23.75 18 12 66.7 0 0 6 33.3 
Neomycin 30 µg 18 10 55.6 0 0 8 44.4 
Erythromycin 15µg 18 10 55.6 3 16.7 5 27.7 
Chloramphenicol 30 µg  18 16 88.8 1 5.6 1 5.6 
Bacitracin 10 µg 18 18 100 0 0 0 0 
Lincomycin 2 µg 18 11 61.1 0 0 7 38.9 
Mean  ±   SEM  9.9 ± 
1.734935 
 0.9 ± 
0.378594 
 7.2 ± 1.756259  


















































Figure 1: Types of resistance traits exhibited by the clinical isolates tested 
 
Table 4: Summary of EPA findings on MDR isolates with TFMBP (200µg/ml) as EPI 
 
Isolate Source Efflux pump activity with TFMBP 




Tetracycline Ciprofloxacin Amoxicillin Cefuroxime  
S. aureus Semen - 2 - - 1 
S. aureus Ear swab 2 2 - - 2 
S. aureus Blood - - - - 0 
S. aureus Eye swab - - - - 0 
S. aureus Eye swab - - - 4 1 
S. aureus Sputum - - - 2 1 
S. aureus Blood - - - - 0 
S. aureus Catheter - - - - 0 
S. lentus Semen - 2 - - 1 
S. lentus Ear swab 4 4 - - 2 
S. xylosus Wound 4 4 - - 2 
Micrococcus sp. Blood 4 16 - 2 3 
Total*  4 6 0 3  
TFMBP: Trifluoro-methyl, benzyl piperazine, EPA: Efflux pump activity, EPI: Efflux pump inhibitor; - Less than 2 
fold reduction in MIC; * total number of bacterial strains with reduced EPA 
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Figure 2: Agarose gel electrophoresis of NorA(Res), NorA(efflux) and MecA amplicons. Key: M = Molecular size 




All the ceftriaxone-resistant strains studied were 
MDR. Some of these were ORSA but were 
susceptible to sulphamethoxazole/trimethoprim. 
This proves that sulphamethoxazole/trimethoprim 
has a good spectrum of activity against S. 
aureus, including several ORSA strains [15]. 
 
The frequency of MRSA among the clinical 
isolates tested corroborates the findings of Zinn 
et al in Southern European countries, some parts 
of the United States, Asia and South Africa [16]. 
Though this frequency is lower than the one 
recorded by Hong et al [17], from tertiary 
hospitals in Korea, it is a trend that needs to be 
surveyed regularly and checked. In this study, 
not all of the MDR isolates were sensitive to 
lincomycin, suggesting that lincosamides have a 
moderate spectrum of activity for S. aureus, 
including some MRSA while all of the 
Staphylococcus spp. were found to be resistant 
to both ampicillin and penicillin suggesting all of 
the species to be penicillinase-producing. 
 
However, studies conducted in hospitals in 
Northern Europe, United States, New Zealand, 
and Australia recorded a much lower frequency 
[16] than was observed in this study. This may 
suggest effective control of antibiotics use 
compared to our environment, where there is 
less control. 
 
When compared with this study, Shittu et al [6] 
recorded a lower percentage (16 %) of ORSA 
from clinical and non-clinical sources from 
different parts of Nigeria. They also recorded 
lower resistance to tetracycline compared with 
the results from this study. Our results may be 
evidence of widespread exposure to antibiotics in 
the hospital environment, suggestive of hospital-
acquired resistance traits compared to non-
clinical environments.  
 
All of the ORSA strains were confirmed as MDR 
S. aureus, which were resistant to at least four 
classes of antibiotics similar to other findings 
[18]. Some of the clinical isolates that turned out 
to be MDR and ORSA strains may not pose any 
clinical risk on their own. The fact that they are 
isolated from the vicinity of infections and around 
patients pose the danger of dissemination of 
dangerous genetic traits to less harmful 
pathogenic strains around them [19]. This can 
lead to complications in therapy of otherwise 
easily-treatable disease conditions. Therefore, 
the occurrence of such MDR and ORSA traits in 
the supposed non-pathogenic organisms cannot 
be overlooked. 
 
As observed in this study, the EPI (TFMBP), with 
an intrinsic MIC > 400 µg/mL, is unlikely to have 
any appreciable antibacterial activity of its own 
[20]. It was found to appreciably lower MICs of 
up to two or three drugs in some of the MDR 
isolates tested. This is consistent with other 
reports [21,22] that a single pump is able to 
confer resistance to multiple compounds. The 
efflux pump inhibition in organisms from the 
various clinical sources tested further 
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underscores the suggestion that the use of such 
inhibitors, in association with substrate 
antibiotics, may be useful for increasing both the 
activity and the range of species for which such 
drugs may be effective [23]. Therefore, it is 
important to do more research on EPIs in 
combating MDR strains. This may help in 
reducing the threat of EPA in resistance 
mechanisms among these organisms. It is 
pertinent to mention that the findings in this study 
are in support of the prediction that the use of 
bacterial resistance modifiers, such as EPIs, 
could facilitate the re-introduction of 
therapeutically-ineffective antibiotics [22], such 
as tetracycline, amoxicillin, and others, back into 
clinical use and might even suppress the 
emergence of MDR strains, if effectively 
managed. 
 
In this study, all the S. aureus isolates with 
phenotypic resistance to oxacillin were tested for 
the carriage of the mecA, Luk-PV, Nor-A (efflux) 
and Nor-A (resistance) genes. None of these 
genes were detected in the tested isolates. This 
is similar to the result obtained in other works 
[24] in which mecA gene was not found in the 
tested MRSAs.  Other genes such as the Luk-PV 
for the PVL gene in the ORSAs were not present 
in the isolates tested, this is corroborated in the 
result obtained from other workers in which PVL 
in MRSA was not isolated but PVL in MSSA was 
observed [25].  
 
From this study, it may be suggested that MDR 
Staphylococcus and Micrococcus obtained from 
clinical isolates should be tested to determine the 
type of resistance involved. This in turn will be a 
guide for proper selection of the antibiotics for 
the treatment regimen. 
 
This study also confirms that clinical isolates 
from the hospital environment could possess the 
EPA mechanism of drug resistance which could 
be tackled with a suitable EPI. Non-detection of 
Luk-PV and mecA in the MRSA isolates might be 
due to the absence of the genes in these isolates 
or that the genes tested may not be indigenous 
to our environment suggesting the possibility of 
other genes yet unknown to be responsible for 




This work presents a new development in 
pharmaceutical microbiology, as it demonstrates 
that the emergence of efflux pump resistance 
mechanisms among MDR strains of 
Staphylococcus and Micrococcus species can be 
tackled by using a suitable EPI, such as TFMBP, 
in antibacterial formulations. Further investigation 
of other suitable EPIs will be of great benefit to 
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